Background: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor,
or statin, that has been developed for the treatment of dyslipidemia. Objective: This study …

Rosuvastatin (Crestor®; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka,
Japan) is a new statin with pharmacologic characteristics that translate into selectivity of …

Background: Although the effect of statins on lowering low-density lipoprotein cholesterol
(LDL-C) has been extensively studied, their hypotriglyceridemic capacity is not fully …

Although large-scale statin trials have demonstrated significant reductions in cardiovascular
risk, there are many patients who have a cardiovascular event despite receiving statin …

Background: Assessments of the effectiveness and cost-effectiveness of treatment with
statins in highrisk patients in routine clinical practice are needed. The objective of the …

BACKGROUND:: Patients with severe hypercholesterolemia may need greater cholesterol
reductions than can beachieved with statin therapy alone. OBJECTIVE:: The primary …

The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on
several nonlipid metabolic variables, along with its safety and tolerability, in patients treated …

OBJECTIVE To evaluate attainment of the National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III low-density lipoprotein cholesterol (LDL-C) goal of less than …

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique
pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration …

Background—Statins are currently the mainstay of dyslipidemia management for the primary
and secondary prevention of cardiovascular disease. Controversial concerns about the …